The Plaquex® Formula has been in use for the past 55 years in about one-fourth of the world’s countries(1). It was originally developed to dissolve fatty embolus during and after trauma surgery. It was also used to treat liver disease(2).
In the 1990’s the use shifted to treating plaque deposits. The treatment was mostly done in combination with EDTA chelation infusions. Since then results have been so dramatic, that it has become a treatment in its own right.
Not only is the Plaquex® Formula used to remove fatty and hardened plaque from blood vessels, it is also applied for general anti aging purposes. By observing their patients, many doctors discovered that the patients started looking younger and healthier after the have had about 20 treatments.
What is Plaquex ?
Plaquex is a natural substance, that is part of every living cell (plant cell, animal cell and human cell). The exact chemical name is phosphatidylcholine. This is a molecule made of glycerine and 2 poly-unsaturated fatty acids. It belongs to the group of Di-Ester molecules.
All cell walls are mainly made out of phosphatidylcholine. 70% of a human cell wall is phosphatidylcholine and 30% is phosphatidylserine.
In a watery solution, phospholipids build double layered membranes. In between the double layered phopholipid molecules structural proteins and also LDL cholesterol are inserted to help with the exchange of substances through the cell wall and to give the cell wall stability.
WHY DOES PLAQUEX WORK ?
Damage to the cell membrane leads to LDL cholesterol being thrown out of the membrane structure, leading to elevated LDL cholesterol in the blood serum. This damage to cell walls is caused by free radicals, toxic substances and detergents that reduce the surface tension. It can also be caused by heart catheters in narrow curves “scratching” the inner lining of the coronary vessels. This leads to a higher need for phosphatidylcholine. The body’s own synthesis isn’t enough to effect repairs. Thus scar tissue replaces the damage and plaques form inside of blood vessels. Therefore it is logical to supplement phosphatidylcholine by infusion when cell membrane damage exists. Oral supplementation is usually absorbed by the liver to repair liver damage and only minute amounts end up in other places. This is the reason oral phosphatidylcholine has little effect on blood vessels. In case of inflammation, damage to blood vessels can be stopped by phosphatidylcholine.
In addition LDL cholesterol is reintegrated into the cell membrane and the serum LDL cholesterol normalizes. LDL cholesterol that has been oxidized by free radicals is bound in to micelles by phosphatidylcholine and transported to the liver where it is metabolized or excreted with gall fluid. The viscosity of the blood – the blood flow characteristics – is also improved.
The main place of action by Plaquex is the entire capillary net. The exchange of substances such as oxygen and nutrients is improved in all tissues.
Plaquex and Aging
With aging the membranes lipid ratios and structures change and degrade. Slowly the cells lose their youthful elasticity, shape and function. The cell membrane no longer admits nourishment into the cell, it no longer allows waste to leave the cell. Over time the age related changes to the cell membrane cause the cell to lie fallow. The cells sleep as if dead.
“Age” related changes in the cell membrane cause all cells, tissues and organs to fail, some earlier, some later.
Plaquex lipid replacement therapy reverses not only plaque in the arteries but reverses the aging process. Receptor and enzyme functions resume. The cell returns to an earlier shape and a more youthful function. The cells become elastic again, nourishment gains entry into the cell, waste is removed and aging is slowed down or even stopped.
1 Elevation of HDL, LDL, and liver enzymes in the beginning which normalize with continuing treatment
Leuschner, F. A. Leuschner. Research report no. 0050/84 of December 27, 1983
Maeda, A. et al. Gendai no Shinryo 22 (1980) 189-192 and 1461-1465
Fasoli, A. Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs
G. Ricci et al. (eds.) Raven Press: New York 1982, 257-262
Suo, T. et al. Kiso to Rinsho 15 (1981) 3046-3051
Belousova, S.S. et al. Kardiologiya 25 (1985) 112-115
Izumi, H. et al. 11th Proceed Jap. Atheroscl. Socl, Tokyo 1979
Nakamura, H. et al. Jap J. New. Rem. Clin. 22 (1973) 1565-1575
Spigai, C. Med. Heute 19 (1970) 197-198
Thurnherr A. Therapiewoche 7 (1956) 116
Friehe, H., R. Fontaine Report no. 840160 of December 16, 1978
Arsenio, L. et al. Clin. Ter. 114 (1985) 117-127
Tomasevic, M. Unpublished report no. 842746
Takahashi, S. Shinryo to Shinyaku 17 (1980) 3051-3064
Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38
2 Angina Pectoris
Serkova, V.K. Klin. Med. (Moscow) 64 (1986) 91-95
Spesivtseva, V. G. et al., Lipostabil Symposium Moscow, Nov. 1984
Kalmykova, V.I., E. B. Zakharova, Sov. Med. 4 (1989) 5-9
Klemm, J. In: Phosphatidylcholine. H. Peeters (ed.) Springer: Berlin 1976, 237-243
Luczac, Z., R. Leutschaft. Unpublished report no. 842762
Pristautz, H. Munch. Med. Wschr. 117 (1975) 583-586
Hevelke, G. et al. Med. Welt 30 (1980) 593-602
Salvioli, G. et al. Il Fegato 21 (1975) 5-25 and: 4th Int. Sympos. Atheroscl., Tokyo 1976 and:
Diab. Obes. Hyperlipoprot., Cupaldi, V. et al. (eds.), Academic Press: New York 1987 Salvioli, G. Scand J. Gastroenterology 12 (1977) 841-847
Salvioli, G. et al. Gut 19 (1978) 844-850
Gaskina, T.K. et al. Voprosy meditsinskoi khimii 331 (1987) 96-99
Ehrly, A.M. Report no. 842276 of March 17, 1975 – and R. Blendin in: Phosphatidylcholine, H. Peeters (ed.) Springer: Berlin 1976, 228-236
Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38
3 Nei’mark Al, Zhukov, VN et al. Use of isradipine and EPL for protection of the kidney during extracorporal lithotripsy
Urologiia I Nefrologiia. (6):19-21, 1998 Nov-Dec
4 Kuntz, E. The “essential” phospholipids in hepatology – 50 years of experimental and clinical experiences Z Gastroenterol (Suppl 2) 1991: 29:7-13
(Information on Plaquex® from www.plaquex.net)